Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Non-small-cell lung cancer (NSCLC) (EGFR m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Epidermal growth factor receptor (EGFR) mutations are significant driver mutations in non-small-cell lung cancer (NSCLC).
Lu et al. 2022b Expert Opinion on Emerging Drugs 27(2): 111-126

These mutations typically occur in exons 18–21 and are crucial for understanding the disease's progression and treatment options.
Robichaux et al. 2021 Nature 597: 732

Types of EGFR Mutations

EGFR Activating Mutations are among the most common genetic alterations, occurring in approximately 21% of Non-small-cell lung cancer (NSCLC) (EGFR m) patients. The prevalence varies based on factors such as smoking status, histology, ethnicity, and gender
Shigematsu et al. 2005 J Natl Cancer Inst 97(5): 339-346

EGFR Mutations in NSCLC

Robichaux et al. 2021 Nature 597…

References (Sources)

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu et al. 2005 J Natl Cancer Inst 97(5): 339-346
Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations
Zheng et al. 2019
EGFR mutation-positive NSCLC: factors to consider when deciding 1st line therapy
Hulo et al. 2020 Exp Rev Anticancer Ther 20: 365-372
Review
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Piper-Vallillo et al. 2020 JCO 38: 2926–2936
Review
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
Lu et al. 2022b Expert Opinion on Emerging Drugs 27(2): 111-126
Review
How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive NSCLC?
Hochmair 2019
Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers
O'Sullivan et al. 2022 Curr Oncol 29(10): 7198-7208

AI Chat

7/1/2026

Chat with our artificial intelligence: